Remix Therapeutics

Private

#RNA Processing #mRNA Degradation #Small Molecule Therapeutics

Remix Therapeutics is a clinical-stage biotechnology company developing small-molecule RNA-targeted therapeutics that modulate RNA processing. The company announced a reverse merger with Passage Bio in 2026 to take Passage's Nasdaq listing while advancing its lead mRNA degrader program.

Company Info

Sector:Biotechnology / RNA Therapeutics / Small Molecule

Headquarters:Cambridge, Massachusetts, USA

Founded:2018

Website:www.remixtx.com/

Upcoming Milestones & Key Dates

TBD 2026

Corporate

Closing of reverse merger with Passage Bio; Nasdaq listing

Clinical Development Pipeline

REM-422

Target: mRNA degrader (MYB / MYBL1)

Multiple myeloma / adenoid cystic carcinoma

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Remix to take Nasdaq spot of Passage Bio in reverse merger for mRNA degrader ↗

Remix Therapeutics will go public via reverse merger with Passage Bio, taking its Nasdaq listing alongside a $100M placement as it advances mRNA degrader REM-422 in cancer.

Leadership Team

Pete Smith, Ph.D.

Co-Founder and Chief Executive Officer

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →